Cristian Bologa
Cristian Bologa
Research Professor, University of New Mexico
Verified email at
Cited by
Cited by
A comprehensive map of molecular drug targets
R Santos, O Ursu, A Gaulton, AP Bento, RS Donadi, CG Bologa, ...
Nature reviews Drug discovery 16 (1), 19-34, 2017
Virtual and biomolecular screening converge on a selective agonist for GPR30
CG Bologa, CM Revankar, SM Young, BS Edwards, JB Arterburn, ...
Nature chemical biology 2 (4), 207-212, 2006
In vivo effects of a GPR30 antagonist
MK Dennis, R Burai, C Ramesh, WK Petrie, SN Alcon, TK Nayak, ...
Nature chemical biology 5 (6), 421-427, 2009
Identification of a GPER/GPR30 Antagonist with Improved Estrogen Receptor Counterselectivity
MK Dennis, AS Field, R Burai, C Ramesh, WK Petrie, CG Bologa, ...
The Journal of Steroid Biochemistry and Molecular Biology, 2011
Drug repurposing from an academic perspective
TI Oprea, JE Bauman, CG Bologa, T Buranda, A Chigaev, BS Edwards, ...
Drug Discovery Today: Therapeutic Strategies 8 (3-4), 61-69, 2011
Virtual screening in drug discovery
J Alvarez, B Shoichet
CRC press, 2005
DrugCentral: online drug compendium
O Ursu, J Holmes, J Knockel, CG Bologa, JJ Yang, SL Mathias, SJ Nelson, ...
Nucleic acids research, gkw993, 2016
Unexplored therapeutic opportunities in the human genome
TI Oprea, CG Bologa, S Brunak, A Campbell, GN Gan, A Gaulton, ...
Nature reviews Drug discovery 17 (5), 317, 2018
Modulation of bitter taste perception by a small molecule hTAS2R antagonist
JP Slack, A Brockhoff, C Batram, S Menzel, C Sonnabend, S Born, ...
Current Biology 20 (12), 1104-1109, 2010
Pharos: Collating protein information to shed light on the druggable genome
DT Nguyen, S Mathias, C Bologa, S Brunak, N Fernandez, A Gaulton, ...
Nucleic acids research 45 (D1), D995-D1002, 2017
Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists
BS Edwards, C Bologa, SM Young, KV Balakin, ER Prossnitz, ...
Molecular pharmacology 68 (5), 1301-1310, 2005
A crowdsourcing evaluation of the NIH chemical probes
TI Oprea, CG Bologa, S Boyer, RF Curpan, RC Glen, AL Hopkins, ...
Nature chemical biology 5 (7), 441-447, 2009
Microbial efflux pump inhibition: tactics and strategies
G P Tegos, M Haynes, J Jacob Strouse, M Md T Khan, C G Bologa, ...
Current pharmaceutical design 17 (13), 1291-1302, 2011
Lead-like, drug-like or “Pub-like”: how different are they?
TI Oprea, TK Allu, DC Fara, RF Rad, L Ostopovici, CG Bologa
Journal of computer-aided molecular design 21 (1-3), 113-119, 2007
Associating drugs, targets and clinical outcomes into an integrated network affords a new platform for computer‐aided drug repurposing
TI Oprea, SK Nielsen, O Ursu, JJ Yang, O Taboureau, SL Mathias, ...
Molecular informatics 30 (2‐3), 100-111, 2011
An automated PLS search for biologically relevant QSAR descriptors
M Olah, C Bologa, TI Oprea
Journal of computer-aided molecular design 18 (7-9), 437-449, 2004
A Potent and Selective Inhibitor of Cdc42 GTPase
Z Surviladze, A Waller, JJ Strouse, C Bologa, O Ursu, V Salas, ...
Strategies for compound selection
MM Olah, CG Bologa, TI Oprea
Current Drug Discovery Technologies 1 (3), 211-220, 2004
High-throughput screening with HyperCyt® flow cytometry to detect small molecule formylpeptide receptor ligands
SM Young, C Bologa, ER Prossnitz, TI Oprea, LA Sklar, BS Edwards
Journal of biomolecular screening 10 (4), 374-382, 2005
Structural Simplification of Bioactive Natural Products with Multicomponent Synthesis. 3. Fused Uracil-Containing Heterocycles as Novel Topoisomerase-Targeting Agents
NM Evdokimov, S Van slambrouck, P Heffeter, L Tu, B Le Calvé, ...
Journal of Medicinal Chemistry 54 (7), 2012-2021, 2011
The system can't perform the operation now. Try again later.
Articles 1–20